Skip to main content
Top
Published in: Endocrine Pathology 2/2011

01-06-2011

Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 Mutations in Thyroid Cancers

Authors: Avaniyapuram Kannan Murugan, Jianli Dong, Jingwu Xie, Mingzhao Xing

Published in: Endocrine Pathology | Issue 2/2011

Login to get access

Abstract

Frequent mutations in the GNAQ, MMP8, Akt3, EGFR, and PIK3R1 genes have been reported in human cancers but mostly have not been well examined in thyroid cancer. Selected exons of GNAQ, MMP8, AKT3, EGFR, and PIK3R1 genes were sequenced in various thyroid cancers. We found a G2203A EGFR mutation, resulting in a G735S amino acid change, in one of 21 (5%) papillary thyroid cancer samples. We did not find any mutation in the MMP8 gene, but observed a frequent SNP A259G (K87E) genotype switch in various types of thyroid cancer samples. We did not find any mutation in the GNAQ, AKT3, and PIK3R1genes in various types of thyroid cancer. No mutation in these genes was found in 12 cell lines derived from various types of thyroid cancer. Therefore, unlike in other cancers, mutations in these genes are uncommon in thyroid cancer.
Literature
1.
go back to reference Leenhardt L, Grosclaude P & Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epdemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14:1056–1060, 2004. Leenhardt L, Grosclaude P & Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epdemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14:1056–1060, 2004.
2.
go back to reference Sprague BL, Warren Andersen S & Trentham-Dietz A. Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Causes and Control 19:585–593, 2008.PubMedCrossRef Sprague BL, Warren Andersen S & Trentham-Dietz A. Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Causes and Control 19:585–593, 2008.PubMedCrossRef
3.
go back to reference Hundahl, I.D. Fleming, A.M. Fremgen and H.R. Menck, A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer 83:2638–2648, 1998.PubMedCrossRef Hundahl, I.D. Fleming, A.M. Fremgen and H.R. Menck, A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer 83:2638–2648, 1998.PubMedCrossRef
4.
go back to reference Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106–3116, 2008.PubMedCrossRef Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106–3116, 2008.PubMedCrossRef
5.
go back to reference Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and bluenaevi. Nature 457:599–602, 2009.PubMedCrossRef Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and bluenaevi. Nature 457:599–602, 2009.PubMedCrossRef
6.
go back to reference Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P, et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet 41:518–520, 2009.PubMedCrossRef Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P, et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet 41:518–520, 2009.PubMedCrossRef
7.
go back to reference Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, et al. A novel AKT3 mutation in melanoma tumors and cell lines. Br J Cancer 99:1265–1268, 2008.PubMedCrossRef Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, et al. A novel AKT3 mutation in melanoma tumors and cell lines. Br J Cancer 99:1265–1268, 2008.PubMedCrossRef
8.
go back to reference Dutt A, Salvesen HB, Greulich H, Sellers WR, Beroukhim R & Meyerson M. Somatic mutations are present in all members of the AKT family in endometrial carcinoma. Br J Cancer 101:1218–1219, 2009.PubMedCrossRef Dutt A, Salvesen HB, Greulich H, Sellers WR, Beroukhim R & Meyerson M. Somatic mutations are present in all members of the AKT family in endometrial carcinoma. Br J Cancer 101:1218–1219, 2009.PubMedCrossRef
9.
go back to reference Masago K, Asato R, Fujita S, Hirano S, Tamura Y, Kanda T, et al., Epidermal growth factor receptor mutations in papillary thyroid carcinoma. Int J Cancer 124:2744–2749, 2009.PubMedCrossRef Masago K, Asato R, Fujita S, Hirano S, Tamura Y, Kanda T, et al., Epidermal growth factor receptor mutations in papillary thyroid carcinoma. Int J Cancer 124:2744–2749, 2009.PubMedCrossRef
10.
go back to reference Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, et al. Somatic mutations in p85α promote tumorigenesis through class 1A PI3K activation. Cancer Cell 16:463–474, 2009.PubMedCrossRef Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, et al. Somatic mutations in p85α promote tumorigenesis through class 1A PI3K activation. Cancer Cell 16:463–474, 2009.PubMedCrossRef
11.
go back to reference Matsuse M, Mitsutake N, Nishihara E, Rogounovitch T, Saenko V, Rumyantsev P, et al. Lack of GNAQ hotspot mutation in papillary thyroid carcinomas. Thyroid 19: 921–922, 2009.PubMedCrossRef Matsuse M, Mitsutake N, Nishihara E, Rogounovitch T, Saenko V, Rumyantsev P, et al. Lack of GNAQ hotspot mutation in papillary thyroid carcinomas. Thyroid 19: 921–922, 2009.PubMedCrossRef
12.
go back to reference Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V, et al. Mutational profile of GNAQQ209 in human tumors. PLoS One 4:e6833, 2009.PubMedCrossRef Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V, et al. Mutational profile of GNAQQ209 in human tumors. PLoS One 4:e6833, 2009.PubMedCrossRef
13.
go back to reference Cassol CA, Guo M, Ezzat S, Asa SL. GNAq mutations are not identified in papillary thyroid carcinomas and hyperfunctioning thyroid nodules. Endocr Pathol 21:250–252, 2010.PubMedCrossRef Cassol CA, Guo M, Ezzat S, Asa SL. GNAq mutations are not identified in papillary thyroid carcinomas and hyperfunctioning thyroid nodules. Endocr Pathol 21:250–252, 2010.PubMedCrossRef
14.
go back to reference Sozopoulos E, Litsiou H, Voutsinas G, Mitsiades N, Anagnostakis N, Tseva T, et al. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece. Endocr Pathol 21:90–100, 2010.PubMedCrossRef Sozopoulos E, Litsiou H, Voutsinas G, Mitsiades N, Anagnostakis N, Tseva T, et al. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece. Endocr Pathol 21:90–100, 2010.PubMedCrossRef
15.
go back to reference Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 91:3662–3666, 2006.PubMedCrossRef Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 91:3662–3666, 2006.PubMedCrossRef
16.
go back to reference Murugan AK, Dong J, Xie J & Xing M. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle 8:2122–2124, 2009.PubMedCrossRef Murugan AK, Dong J, Xie J & Xing M. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle 8:2122–2124, 2009.PubMedCrossRef
17.
go back to reference Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65:7276–7282, 2005.PubMedCrossRef Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65:7276–7282, 2005.PubMedCrossRef
18.
go back to reference Tsao MA, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353:133–144, 2005.PubMedCrossRef Tsao MA, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353:133–144, 2005.PubMedCrossRef
19.
go back to reference Douglas DA, Zhong H, Ro JY, Oddoux C, Berger AD, Pincus MR, et al. Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front Biosci 11:2518–2525, 2006.PubMedCrossRef Douglas DA, Zhong H, Ro JY, Oddoux C, Berger AD, Pincus MR, et al. Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front Biosci 11:2518–2525, 2006.PubMedCrossRef
20.
go back to reference Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, Liebes L, et al. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene 27:3201–3210, 2008.PubMedCrossRef Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, Liebes L, et al. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene 27:3201–3210, 2008.PubMedCrossRef
21.
go back to reference Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 6:6105–6111, 2001. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 6:6105–6111, 2001.
22.
go back to reference Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885–4893, 2009.PubMedCrossRef Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885–4893, 2009.PubMedCrossRef
Metadata
Title
Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 Mutations in Thyroid Cancers
Authors
Avaniyapuram Kannan Murugan
Jianli Dong
Jingwu Xie
Mingzhao Xing
Publication date
01-06-2011
Publisher
Springer US
Published in
Endocrine Pathology / Issue 2/2011
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-011-9155-x

Other articles of this Issue 2/2011

Endocrine Pathology 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine